{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:30:32Z","timestamp":1784233832954,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jns.2023.120693","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T20:22:53Z","timestamp":1685391773000},"page":"120693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders"],"prefix":"10.1016","volume":"451","author":[{"given":"Allison","family":"Osen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Stefoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian Sierra","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S2","key":"10.1016\/j.jns.2023.120693_bb0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10072-009-0145-4","article-title":"Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks","volume":"30","author":"Rinaldi","year":"2009","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2023.120693_bb0010","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1007\/s10072-021-05052-1","article-title":"Cyclophosphamide treatment in active multiple sclerosis","volume":"42","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2023.120693_bb0015","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.jns.2023.120693_bb0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0022-510X(83)90224-1","article-title":"Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression","volume":"58","author":"Hommes","year":"1983","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2023.120693_bb0025","first-page":"84","article-title":"Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases","volume":"3","author":"DeZern","year":"2013","journal-title":"American J. Blood Res."},{"key":"10.1016\/j.jns.2023.120693_bb0030","article-title":"Cyclophosphamide in treatment of tumefactive multiple sclerosis","volume":"47","author":"Fereidan-Esfahani","year":"2021","journal-title":"Mult. Sclero. Relat. Disord."},{"issue":"7","key":"10.1016\/j.jns.2023.120693_bb0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga\u00f1a","year":"2011","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2023.120693_bb0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2023.120693_bb0045","series-title":"Cyclophosphamide therapy for multiple sclerosis","first-page":"171191","author":"Smith","year":"2005"},{"issue":"4","key":"10.1016\/j.jns.2023.120693_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2023.120693_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2023.120693_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive Immunosuppression in Progressive Multiple Sclerosis","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2023.120693_bb0065","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1212\/WNL.43.5.910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the northeast cooperative multiple sclerosis treatment group","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2023.120693_bb0070","article-title":"Comment on: Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases","volume":"14","author":"Nicoletti","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.jns.2023.120693_bb0075","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/art.39068","article-title":"Adult primary central nervous system Vasculitis treatment and course: analysis of one hundred sixty-three patients","volume":"67","author":"Salvarani","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.jns.2023.120693_bb0080","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/art.38340","article-title":"Primary Angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary Vasculitis of the central nervous system","volume":"66","author":"de Boysson","year":"2014","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jns.2023.120693_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2023.120693_bb0090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J. Neurol., Neurosurg. Psychiat."},{"issue":"9","key":"10.1016\/j.jns.2023.120693_bb0095","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Beh\u00e7et\u2019s syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2019","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.jns.2023.120693_bb0100","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis a 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthrit. Rheumat."},{"issue":"1","key":"10.1016\/j.jns.2023.120693_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(87)90490-6","article-title":"Malignancy following treatment of rheumatoid arthritis with cyclophosphamide","volume":"83","author":"Baker","year":"1987","journal-title":"Am. J. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:01:51Z","timestamp":1758384111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X23001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":21,"alternative-id":["S0022510X23001533"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.120693","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.120693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120693"}}